| 治部真里,李颖.基于新指标体系的制药产业现状俯瞰与未来预测[J].情报工程,2015,1(1):16-27 |
| 基于新指标体系的制药产业现状俯瞰与未来预测 |
| An Overview and Future Prospects of Pharmaceutical Industry Based on New Indicators |
| |
| DOI：doi:10.3772/j.issn.2095-915x.2015.01.002 |
| 中文关键词: 日本版 NIH，在研药物，指标，低分子化合物，生物制药，生物技术，循证政策 |
| 英文关键词: Japanese version of the NIH, pipeline, indicator, small molecules, bio-medicine, biotechnology, evidence based policy |
| 基金项目:国家 自然科学基金项目“面向专利文献的统计机器翻译语境分析”( 项目编号：61303152) 和中日国际合作项目“面向科技文献的日汉双向实用型机器翻译合作研究”( 项目编号：2014DFA11350) |
|
| 摘要点击次数: 3735 |
| 全文下载次数: 2848 |
| 中文摘要: |
| 日本版 NIH 及其制药企业，政策制定·战略规划需要佐证。为此，本研究尝试基于新的指标体系
进行制药产业的现状俯瞰与未来预测。连载第一篇，着眼于制药产业研究开发的 pipeline，即在研药物。按照研究开发阶段来梳理 pipeline，通过与已上市药物数量的比较，显然可以把握各国目前及未来的研发能力。该结果凸现出了美国在研发中的优势，以及日本的特异性等。 |
| 英文摘要: |
| For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried an overview and future prospects of pharmaceutical industry based on new indicators. We focused on the R&D pipelines of each pharmaceutical company. The results show that the R&D capacity of each country in the current stage and in future can be measured, by structuring the pipeline data in each R&D step, comparing the number of marketed pharmaceuticals and so on. Consequently, the competitive advantage of US and the idiosyncrasy of Japan have been thrown into sharp relief. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
